The buildup of lipid peroxides on the cell membrane is critical in the initiation of Ferroptosis, an iron-dependent form of controlled cell death. Ferroptosis is a type of cell death that varies from other types of cell death in both mechanics and morphology, and it holds significant promise for cancer therapy. As a result, there has been increasing interest in the cancer research community regarding the exploration and understanding of Ferroptosis in recent years. This review article aims to provide a solid theoretical foundation for the management of Ferroptosis in cancer. It accomplishes this by summarizing the processes that contribute to the development of Ferroptosis and outlining the underlying mechanisms of Ferroptosis in various types of tumors.

1. Sadri Nahand, J., et al., Pathogenic role of exosomes and microRNAs in HPV‐mediated inflammation and cervical cancer: a review. International journal of cancer, 2020. 146(2): p. 305-320.

2. Cheng, Y., et al., Ferroptosis mediated by lipid reactive oxygen species: a possible causal link of neuroinflammation to neurological disorders. Oxidative Medicine and Cellular Longevity, 2021. 2021: p. 1-13.

3. Li, J., et al., Ferroptosis: past, present and future. Cell death & disease, 2020. 11(2): p. 88.

4. Liu, Y., et al., Effects of ferroptosis on male reproduction. International Journal of Molecular Sciences, 2022. 23(13): p. 7139.

5. Dixon, S.J., Ferroptosis: bug or feature? Immunological reviews, 2017. 277(1): p. 150-157.

6. Ma, L., et al., Paeoniflorin alleviates ischemia/reperfusion induced acute kidney injury by inhibiting Slc7a11-mediated ferroptosis. International Immunopharmacology, 2023. 116: p. 109754.

7. Conrad, M., et al., Regulation of lipid peroxidation and ferroptosis in diverse species. Genes & development, 2018. 32(9-10): p. 602-619.

8. Liu, R., et al., Cystine-glutamate transporter SLC7A11 mediates resistance to geldanamycin but not to 17-(allylamino)-17-demethoxygeldanamycin. Molecular pharmacology, 2007. 72(6): p. 1637-1646.

9. DeRosa, A. and A. Leftin, The iron curtain: macrophages at the Interface of systemic and microenvironmental iron metabolism and immune response in cancer. Frontiers in Immunology, 2021. 12: p. 614294.

10. Li, Z., et al., In vivo tracking cystine/glutamate antiporter-mediated cysteine/cystine pool under ferroptosis. Analytica Chimica Acta, 2020. 1125: p. 66-75.

11. Wang, L., X. Chen, and C. Yan, Ferroptosis: An emerging therapeutic opportunity for cancer. Genes & Diseases, 2022. 9(2): p. 334-346.

12. Zhao, L., et al., Ferroptosis in cancer and cancer immunotherapy. Cancer Communications, 2022. 42(2): p. 88-116.

13. Zhao, Y., et al., The Role of Erastin in Ferroptosis and Its Prospects in Cancer Therapy. OncoTargets and Therapy, 2020. Volume 13: p. 5429-5441.

14. Ju, J., Y.-n. Song, and K. Wang, Mechanism of ferroptosis: a potential target for cardiovascular diseases treatment. Aging and disease, 2021. 12(1): p. 261.

15. Huang, R., et al., Dual role of reactive oxygen species and their application in cancer therapy. Journal of Cancer, 2021. 12(18): p. 5543.

16. Liu, L., et al., Autophagy‐Dependent Ferroptosis as a Therapeutic Target in Cancer. ChemMedChem, 2021. 16(19): p. 2942-2950.

17. Zhao, Y., et al., The role of erastin in ferroptosis and its prospects in cancer therapy. OncoTargets and therapy, 2020. 13: p. 5429.

18. Nguyen, T.H.P., B. Mahalakshmi, and B.K. Velmurugan, Functional role of ferroptosis on cancers, activation and deactivation by various therapeutic candidates-an update. Chemico-biological interactions, 2020. 317: p. 108930.

19. Luo, M., et al., Targeting lipid metabolism for ferroptotic cancer therapy. Apoptosis, 2022: p. 1-27.

20. Wang, Y., Y. Ma, and K. Jiang, The role of ferroptosis in prostate cancer: a novel therapeutic strategy. Prostate Cancer and Prostatic Diseases, 2022: p. 1-5.

21. Wei, Y., et al., Directly targeting glutathione peroxidase 4 may be more effective than disrupting glutathione on ferroptosis-based cancer therapy. Biochimica et Biophysica Acta (BBA)-General Subjects, 2020. 1864(4): p. 129539.

22. Stockwell, B.R., et al., Ferroptosis: a regulated cell death nexus linking metabolism, redox biology, and disease. Cell, 2017. 171(2): p. 273-285.

23. Forcina, G.C. and S.J. Dixon, GPX4 at the crossroads of lipid homeostasis and ferroptosis. Proteomics, 2019. 19(18): p. 1800311.

24. Su, Y., et al., Ferroptosis, a novel pharmacological mechanism of anti-cancer drugs. Cancer Letters, 2020. 483: p. 127-136.

25. Cui, C., F. Yang, and Q. Li, Post-translational modification of GPX4 is a promising target for treating ferroptosis-related diseases. Frontiers in Molecular Biosciences, 2022. 9.

26. Kinowaki, Y., et al., Overview of ferroptosis and synthetic lethality strategies. International Journal of Molecular Sciences, 2021. 22(17): p. 9271.

27. Shimada, K., et al., Global survey of cell death mechanisms reveals metabolic regulation of ferroptosis. Nature chemical biology, 2016. 12(7): p. 497-503.

28. Gaschler, M.M., et al., FINO2 initiates ferroptosis through GPX4 inactivation and iron oxidation. Nature chemical biology, 2018. 14(5): p. 507-515.

29. Lei, P., T. Bai, and Y. Sun, Mechanisms of ferroptosis and relations with regulated cell death: a review. Frontiers in physiology, 2019. 10: p. 139.

30. Liu, J., et al., The regulation of ferroptosis by tumor suppressor p53 and its pathway. International journal of molecular sciences, 2020. 21(21): p. 8387.

31. Chen, D., et al., iPLA2β-mediated lipid detoxification controls p53-driven ferroptosis independent of GPX4. Nature Communications, 2021. 12(1): p. 3644.

32. Jin, Y., W. Gu, and W. Chen, Sirt3 is critical for p53-mediated ferroptosis upon ROS-induced stress. Journal of Molecular Cell Biology, 2021. 13(2): p. 151-154.

33. Wu, Y., et al., The epigenetic regulators and metabolic changes in ferroptosis-associated cancer progression. Molecular cancer, 2020. 19(1): p. 1-17.

34. Zhang, W., et al., Targeted p53 on small-molecules-induced ferroptosis in cancers. Frontiers in oncology, 2018. 8: p. 507.

35. Koppula, P., L. Zhuang, and B. Gan, Cystine transporter SLC7A11/xCT in cancer: ferroptosis, nutrient dependency, and cancer therapy. Protein & cell, 2021. 12(8): p. 599-620.

36. Yuan, H., J. Pratte, and C. Giardina, Ferroptosis and its potential as a therapeutic target. Biochemical pharmacology, 2021. 186: p. 114486.

37. Hassannia, B., P. Vandenabeele, and T.V. Berghe, Targeting ferroptosis to iron out cancer. Cancer cell, 2019. 35(6): p. 830-849.

38. Jiang, L., et al., Ferroptosis as a p53-mediated activity during tumour suppression. Nature, 2015. 520(7545): p. 57-62.

39. Chu, B., et al., ALOX12 is required for p53-mediated tumour suppression through a distinct ferroptosis pathway. Nature cell biology, 2019. 21(5): p. 579-591.

40. Gaschler, M.M. and B.R. Stockwell, Lipid peroxidation in cell death. Biochemical and biophysical research communications, 2017. 482(3): p. 419-425.

41. Zhang, H.-L., et al., PKCβII phosphorylates ACSL4 to amplify lipid peroxidation to induce ferroptosis. Nature cell biology, 2022. 24(1): p. 88-98.

42. Buccellato, F.R., et al., Role of oxidative damage in alzheimer’s disease and neurodegeneration: From pathogenic mechanisms to biomarker discovery. Antioxidants, 2021. 10(9): p. 1353.

43. Zhao, L., et al., Apatinib induced ferroptosis by lipid peroxidation in gastric cancer. Gastric Cancer, 2021. 24: p. 642-654.

44. Song, X. and D. Long, Nrf2 and ferroptosis: a new research direction for neurodegenerative diseases. Frontiers in Neuroscience, 2020. 14: p. 267.

45. Qu, Z., et al., Transcription factor NRF2 as a promising therapeutic target for Alzheimer’s disease. Free Radical Biology and Medicine, 2020. 159: p. 87-102.

46. LI Qiuchang, Y.S., MENG Yazhen, GU Yunxia, NING Qiaoming, LI Na, WANG Zhihua, Neuroprotective effects of dexmedetomidine on intracerebral hemorrhage of rats by Nrf2-GPX4 mediated iron death pathway. Tianjin Medical Journal, 2022. 50(8): p. 817-821.

47. Dodson, M., R. Castro-Portuguez, and D.D. Zhang, NRF2 plays a critical role in mitigating lipid peroxidation and ferroptosis. Redox biology, 2019. 23: p. 101107.

48. Wang, Q., et al., GSTZ1 sensitizes hepatocellular carcinoma cells to sorafenib-induced ferroptosis via inhibition of NRF2/GPX4 axis. Cell death & disease, 2021. 12(5): p. 426.

49. Xie, Y., et al., Ferroptosis: process and function. Cell Death & Differentiation, 2016. 23(3): p. 369-379.

50. Liu, X., et al., Dihydroquercetin suppresses cigarette smoke induced ferroptosis in the pathogenesis of chronic obstructive pulmonary disease by activating Nrf2-mediated pathway. Phytomedicine, 2022. 96: p. 153894.

51. Yan, H.-f., et al., Ferroptosis: mechanisms and links with diseases. Signal transduction and targeted therapy, 2021. 6(1): p. 49.

52. Gao, Q., et al., Opportunities and challenges for co-delivery nanomedicines based on combination of phytochemicals with chemotherapeutic drugs in cancer treatment. Advanced Drug Delivery Reviews, 2022: p. 114445.

53. Gao, R., et al., YAP/TAZ and ATF4 drive resistance to Sorafenib in hepatocellular carcinoma by preventing ferroptosis. EMBO Molecular Medicine, 2021. 13(12): p. e14351.

54. Li, Z.-j., et al., Artesunate synergizes with sorafenib to induce ferroptosis in hepatocellular carcinoma. Acta Pharmacologica Sinica, 2021. 42(2): p. 301-310.

55. Yuan, S., et al., Sorafenib attenuates liver fibrosis by triggering hepatic stellate cell ferroptosis via HIF‐1α/SLC7A11 pathway. Cell Proliferation, 2022. 55(1): p. e13158.

56. Sun, J., et al., Quiescin sulfhydryl oxidase 1 promotes sorafenib-induced ferroptosis in hepatocellular carcinoma by driving EGFR endosomal trafficking and inhibiting NRF2 activation. Redox biology, 2021. 41: p. 101942.

57. Ajoolabady, A., et al., Ferroptosis in hepatocellular carcinoma: mechanisms and targeted therapy. British Journal of Cancer, 2022: p. 1-16.

58. Yu, Y., et al., Arginase 2 negatively regulates sorafenib-induced cell death by mediating ferroptosis in melanoma. Acta Biochimica et Biophysica Sinica, 2022. 54(11): p. 1658-1670.

59. Li, Y., et al., ATF3 promotes ferroptosis in sorafenib-induced cardiotoxicity by suppressing Slc7a11. Frontiers in Pharmacology, 2022: p. 2949.

60. Cai, S., et al., SIRT6 silencing overcomes resistance to sorafenib by promoting ferroptosis in gastric cancer. Biochemical and biophysical research communications, 2021. 577: p. 158-164.

61. Hanly, E.K., et al., Abstract 3709: Resistance mechanisms to targeted molecular therapy in thyroid cancer. Cancer Research, 2014. 74(19 Supplement): p. 3709-3709.

62. Wu, J., et al., Heat shock proteins and cancer. Trends in pharmacological sciences, 2017. 38(3): p. 226-256.

63. Khandia, R., et al., Heat shock proteins: therapeutic perspectives in inflammatory disorders. Recent Patents on Inflammation & Allergy Drug Discovery, 2016. 10(2): p. 94-104.

64. Zhang, B., et al., Multifaceted roles of HSF1 in cell death: A state-of-the-art review. Biochimica et Biophysica Acta (BBA)-Reviews on Cancer, 2021. 1876(2): p. 188591.

65. Tang, D., et al., The dual role of ferroptosis in pancreatic cancer: a narrative review. Journal of Pancreatology, 2021. 4(02): p. 76-81.

66. Sha, W., et al., Mechanism of ferroptosis and its role in type 2 diabetes mellitus. Journal of diabetes research, 2021. 2021.

67. Li, L., et al., NVP-AUY922 alleviates radiation-induced lung injury via inhibition of autophagy-dependent ferroptosis. Cell Death Discovery, 2022. 8(1): p. 86.

68. Sun, X., et al., HSPB1 as a novel regulator of ferroptotic cancer cell death. Oncogene, 2015. 34(45): p. 5617-5625.

69. Amaravadi, R.K. and C.B. Thompson, The roles of therapy-induced autophagy and necrosis in cancer treatment. Clinical cancer research, 2007. 13(24): p. 7271-7279.

70. Liu, J., R. Kang, and D. Tang, Signaling pathways and defense mechanisms of ferroptosis. The FEBS journal, 2022. 289(22): p. 7038-7050.

71. Chen, X., et al., Iron metabolism in ferroptosis. Frontiers in cell and developmental biology, 2020. 8: p. 590226.

72. Latunde-Dada, G.O., Ferroptosis: role of lipid peroxidation, iron and ferritinophagy. Biochimica et Biophysica Acta (BBA)-General Subjects, 2017. 1861(8): p. 1893-1900.

73. Lang, X., et al., Radiotherapy and Immunotherapy Promote Tumoral Lipid Oxidation and Ferroptosis via Synergistic Repression of SLC7A11Ferroptosis Connects Radiotherapy and Immunotherapy. Cancer discovery, 2019. 9(12): p. 1673-1685.

74. Wu, Y., et al., Ferroptosis in cancer treatment: another way to Rome. Frontiers in oncology, 2020. 10: p. 571127.

75. Du, J., et al., DHA exhibits synergistic therapeutic efficacy with cisplatin to induce ferroptosis in pancreatic ductal adenocarcinoma via modulation of iron metabolism. Cell Death & Disease, 2021. 12(7): p. 705.

76. Du, J., et al., Designer exosomes for targeted and efficient ferroptosis induction in cancer via chemo-photodynamic therapy. Theranostics, 2021. 11(17): p. 8185.

77. Sha, R., et al., Predictive and prognostic impact of ferroptosis-related genes ACSL4 and GPX4 on breast cancer treated with neoadjuvant chemotherapy. EBioMedicine, 2021. 71: p. 103560.

78. Zhang, Y., et al., A novel ferroptosis‑related gene signature for overall survival prediction and immune infiltration in patients with breast cancer. International Journal of Oncology, 2022. 61(6): p. 1-16.

79. Li, R., et al., Transcriptome investigation and in vitro verification of curcumin-induced HO-1 as a feature of ferroptosis in breast cancer cells. Oxidative Medicine and Cellular Longevity, 2020. 2020.

80. Li, K., et al., Multienzyme-like reactivity cooperatively impairs glutathione peroxidase 4 and ferroptosis suppressor protein 1 pathways in triple-negative breast cancer for sensitized ferroptosis therapy. ACS nano, 2022. 16(2): p. 2381-2398.

81. Zhang, Z., et al., Holo-lactoferrin: The link between ferroptosis and radiotherapy in triple-negative breast cancer. Theranostics, 2021. 11(7): p. 3167.

82. Yang, J., et al., Metformin induces Ferroptosis by inhibiting UFMylation of SLC7A11 in breast cancer. Journal of Experimental & Clinical Cancer Research, 2021. 40(1): p. 206.

83. Chen, Y., et al., CRISPR screens uncover protective effect of PSTK as a regulator of chemotherapy-induced ferroptosis in hepatocellular carcinoma. Molecular Cancer, 2022. 21(1): p. 1-17.

84. Lu, Y., et al., Epigenetic regulation of ferroptosis via ETS1/miR-23a-3p/ACSL4 axis mediates sorafenib resistance in human hepatocellular carcinoma. Journal of Experimental & Clinical Cancer Research, 2022. 41(1): p. 1-17.

85. Grube, J., et al., ACSL4-dependent ferroptosis does not represent a tumor-suppressive mechanism but ACSL4 rather promotes liver cancer progression. Cell Death & Disease, 2022. 13(8): p. 704.

86. Guan, L., et al., Downregulation of HULC induces ferroptosis in hepatocellular carcinoma via targeting of the miR-3200-5p/ATF4 axis. Oxidative Medicine and Cellular Longevity, 2022. 2022.

87. Battaglia, A.M., et al., Iron administration overcomes resistance to erastin-mediated ferroptosis in ovarian cancer cells. Frontiers in Oncology, 2022. 12.

88. Zou, Q., et al., E3 ubiquitin ligases in cancer stem cells: key regulators of cancer hallmarks and novel therapeutic opportunities. Cellular Oncology, 2023: p. 1-26.

89. You, Y., et al., Ferroptosis-related gene signature promotes ovarian cancer by influencing immune infiltration and invasion. Journal of Oncology, 2021. 2021: p. 1-16.

90. Jing, T., Y. Guo, and Y. Wei, Carboxymethylated pachyman induces ferroptosis in ovarian cancer by suppressing NRF1/HO‑1 signaling. Oncology Letters, 2022. 23(5): p. 1-9.

91. Wei, R., et al., Tagitinin C induces ferroptosis through PERK-Nrf2-HO-1 signaling pathway in colorectal cancer cells. International journal of biological sciences, 2021. 17(11): p. 2703.

92. Li, J., et al., Role of NRF2 in Colorectal Cancer Prevention and Treatment. Technology in Cancer Research & Treatment, 2022. 21: p. 15330338221105736.

93. Broadbridge, V.T., C.S. Karapetis, and T.J. Price, Cetuximab in metastatic colorectal cancer. Expert review of anticancer therapy, 2012. 12(5): p. 555-565.

94. Yang, J., et al., Cetuximab promotes RSL3-induced ferroptosis by suppressing the Nrf2/HO-1 signalling pathway in KRAS mutant colorectal cancer. Cell death & disease, 2021. 12(11): p. 1079.

95. Itchins, M. and N. Pavlakis, The evolving landscape of treatment for advanced gastric cancer and the role of anti-angiogenic therapy: implications from results of the INTEGRATE study. Translational Gastroenterology and Hepatology, 2017. 2.

96. Tian, X., S. Li, and G. Ge, Apatinib promotes ferroptosis in colorectal cancer cells by targeting ELOVL6/ACSL4 signaling. Cancer Management and Research, 2021: p. 1333-1342.

97. Yang, L., et al., Mechanism and application of ferroptosis in colorectal cancer. Biomedicine & Pharmacotherapy, 2023. 158: p. 114102.

98. Chen, X., et al., Broadening horizons: the role of ferroptosis in cancer. Nature reviews Clinical oncology, 2021. 18(5): p. 280-296.

99. Kim, K.-S., et al., Enhanced natural killer cell anti-tumor activity with nanoparticles mediated ferroptosis and potential therapeutic application in prostate cancer. Journal of Nanobiotechnology, 2022. 20(1): p. 428.

100. Cheng, L., et al., SGK2 promotes prostate cancer metastasis by inhibiting ferroptosis via upregulating GPX4. Cell Death & Disease, 2023. 14(1): p. 74.

101. Zuo, Y.-B., et al., Ferroptosis in cancer progression: Role of noncoding RNAs. International Journal of Biological Sciences, 2022. 18(5): p. 1829.

102. Wei, J., et al., A novel ferroptosis-related lncRNA signature for prognosis prediction in gastric cancer. BMC Cancer, 2021. 21(1): p. 1221.

103. Yao, F., et al., LncRNAs target ferroptosis-related genes and impair activation of CD4+ T cell in gastric cancer. Frontiers in cell and developmental biology, 2021: p. 3513.

104. Lu, L., et al., Role of ferroptosis and ferroptosis-related non-coding RNAs in the occurrence and development of gastric cancer. Ferroptosis as New Therapeutic Targets in Cancer: from Molecular Mechanisms to Therapeutic Opportunities, 2022. 2: p. 216.

105. Ni, H., et al., MiR-375 reduces the stemness of gastric cancer cells through triggering ferroptosis. Stem cell research & therapy, 2021. 12(1): p. 1-17.

106. Ying, et al., Physcion 8-O-β-glucopyranoside induced ferroptosis via regulating miR-103a-3p/GLS2 axis in gastric cancer - ScienceDirect. Life Sciences. 237: p. 116893-116893.

107. Zhang, H., et al., CAF secreted miR-522 suppresses ferroptosis and promotes acquired chemo-resistance in gastric cancer. Molecular cancer, 2020. 19: p. 1-17.

108. Rademaker, G., et al., Myoferlin targeting triggers mitophagy and primes ferroptosis in pancreatic cancer cells. Redox Biology, 2022. 53: p. 102324.

109. Valashedi, M.R., et al., Pharmacological targeting of ferroptosis in cancer treatment. Current Cancer Drug Targets, 2022. 22(2): p. 108-125.

110. Li, J., et al., Small-molecule MMRi62 induces ferroptosis and inhibits metastasis in pancreatic cancer via degradation of ferritin heavy chain and mutant p53. Molecular Cancer Therapeutics, 2022. 21(4): p. 535-545.

111. Yang, J., et al., Ferroptosis: At the crossroad of gemcitabine resistance and tumorigenesis in pancreatic cancer. International Journal of Molecular Sciences, 2021. 22(20): p. 10944.

112. Liu, J., et al., NUPR1 is a critical repressor of ferroptosis. Nature communications, 2021. 12(1): p. 647.

113. Chen, X., et al., Targeting ferroptosis in pancreatic cancer: a double-edged sword. Trends in Cancer, 2021. 7(10): p. 891-901.

114. Lu, Y., et al., KLF2 inhibits cancer cell migration and invasion by regulating ferroptosis through GPX4 in clear cell renal cell carcinoma. Cancer Letters, 2021. 522: p. 1-13.

115. Zhang, Y., et al., MITD1 Deficiency Suppresses Clear Cell Renal Cell Carcinoma Growth and Migration by Inducing Ferroptosis through the TAZ/SLC7A11 Pathway. Oxidative Medicine and Cellular Longevity, 2022. 2022.

116. Wang, J., et al., SUV39H1 deficiency suppresses clear cell renal cell carcinoma growth by inducing ferroptosis. Acta Pharmaceutica Sinica B, 2021. 11(2): p. 406-419.

117. Jiang, A., et al., A novel thinking: DDR axis refines the classification of ccRCC with distinctive prognosis, multi omics landscape and management strategy. Frontiers in Public Health, 2022. 10.

118. Dong, L., et al., The Roles of MiRNAs (MicroRNAs) in Melanoma Immunotherapy. International Journal of Molecular Sciences, 2022. 23(23): p. 14775.

119. Wang, S., et al., CAMKK2 defines ferroptosis sensitivity of melanoma cells by regulating AMPK‒NRF2 pathway. Journal of Investigative Dermatology, 2022. 142(1): p. 189-200. e8.

120. Yang, Y., et al., Nedd4 ubiquitylates VDAC2/3 to suppress erastin-induced ferroptosis in melanoma. Nature communications, 2020. 11(1): p. 433.

121. Park, J., M. Yeom, and D.-H. Hahm, Fucoidan improves serum lipid levels and atherosclerosis through hepatic SREBP-2-mediated regulation. Journal of pharmacological sciences, 2016. 131(2): p. 84-92.

122. Battaglia, A.M., et al., Ferroptosis and cancer: mitochondria meet the “iron maiden” cell death. Cells, 2020. 9(6): p. 1505.

123. Gong, D., et al., Role of ferroptosis on tumor progression and immunotherapy. Cell death discovery, 2022. 8(1): p. 427.

124. Luo, M., et al., miR-137 regulates ferroptosis by targeting glutamine transporter SLC1A5 in melanoma. Cell Death & Differentiation, 2018. 25(8): p. 1457-1472.

125. Kadhim, M.M., et al., Autophagy as a self-digestion signal in human cancers: Regulation by microRNAs in affecting carcinogenesis and therapy response. Pharmacological Research, 2023: p. 106695.

126. Puik, J.R., et al., miRNA profiling for diagnosis, prognosis and stratification of cancer treatment in cholangiocarcinoma. Pharmacogenomics, 2017. 18(14): p. 1343-1358.

127. Ni, Y.-H., X. Zhao, and W. Wang, CD24, a review of its role in tumor diagnosis, progression and therapy. Current Gene Therapy, 2020. 20(2): p. 109-126.

128. Yao, X., et al., Exploration and validation of a novel ferroptosis-related gene signature predicting the prognosis of intrahepatic cholangiocarcinoma. Acta Biochimica et Biophysica Sinica, 2022.

129. Voss, J.S., et al., Molecular profiling of cholangiocarcinoma shows potential for targeted therapy treatment decisions. Human pathology, 2013. 44(7): p. 1216-1222.

130. Rizvi, S. and G.J. Gores, Emerging molecular therapeutic targets for cholangiocarcinoma. Journal of hepatology, 2017. 67(3): p. 632-644.

131. Su, L., et al., Isocitrate dehydrogenase 1 mutation in cholangiocarcinoma impairs tumor progression by sensitizing cells to ferroptosis. Open Medicine, 2022. 17(1): p. 863-870.

132. Lei, S., et al., JUND/linc00976 promotes cholangiocarcinoma progression and metastasis, inhibits ferroptosis by regulating the miR-3202/GPX4 axis. Cell Death & Disease, 2022. 13(11): p. 967.

133. Zhu, Z., et al., FBXO31 sensitizes cancer stem cells‐like cells to cisplatin by promoting ferroptosis and facilitating proteasomal degradation of GPX4 in cholangiocarcinoma. Liver International, 2022. 42(12): p. 2871-2888.

134. Jiang, H., et al., ATF4 protects against sorafenib-induced cardiotoxicity by suppressing ferroptosis. Biomedicine & Pharmacotherapy, 2022. 153: p. 113280.

135. Shi, J., et al., Ferroptosis-related gene signature predicts the prognosis of papillary thyroid carcinoma. Cancer Cell International, 2021. 21: p. 1-14.

136. Valashedi, M.R., et al., Non-coding RNAs in ferroptotic cancer cell death pathway: meet the new masters. Human Cell, 2022. 35(4): p. 972-994.

137. Wang, Y., et al., Identification and validation of a prognostic signature for thyroid cancer based on ferroptosis-related genes. Genes, 2022. 13(6): p. 997.

138. Ji, F.-H., et al., FTO prevents thyroid cancer progression by SLC7A11 m6A methylation in a ferroptosis-dependent manner. Frontiers in Endocrinology, 2022. 13.

139. Li, W., et al., ALKBH5 inhibits thyroid cancer progression by promoting ferroptosis through TIAM1–Nrf2/HO-1 axis. Molecular and Cellular Biochemistry, 2022: p. 1-13.

140. Chen, S., et al., CircCDK14 promotes tumor progression and resists ferroptosis in glioma by regulating PDGFRA. International Journal of Biological Sciences, 2022. 18(2): p. 841.

141. Zhang, G., et al., Ferroptosis: A novel therapeutic strategy and mechanism of action in glioma. Frontiers in Oncology, 2022. 12: p. 947530.

142. Liu, L., et al., Cystine‐glutamate antiporter xCT as a therapeutic target for cancer. Cell Biochemistry and Function, 2021. 39(2): p. 174-179.

143. Hu, Z., et al., A potential mechanism of temozolomide resistance in glioma–ferroptosis. Frontiers in oncology, 2020. 10: p. 897.

144. Huang, R., et al., Adaptive changes allow targeting of ferroptosis for glioma treatment. Cellular and Molecular Neurobiology, 2022. 42(7): p. 2055-2074.

145. Li, S., et al., RSL3 drives ferroptosis through NF-κB pathway activation and GPX4 depletion in glioblastoma. Oxidative Medicine and Cellular Longevity, 2021. 2021.

146. Zhang, Y., et al., Loss of COPZ1 induces NCOA4 mediated autophagy and ferroptosis in glioblastoma cell lines. Oncogene, 2021. 40(8): p. 1425-1439.

147. Li, P., et al., The Role of Ferroptosis-Related Molecules and Significance of Ferroptosis Score in Cervical Cancer. Journal of Oncology, 2022. 2022.

148. Zhao, M.-Y., et al., Propofol augments paclitaxel-induced cervical cancer cell ferroptosis in vitro. Frontiers in Pharmacology, 2022. 13.

149. Ou, R., et al., Circular RNA circLMO1 suppresses cervical cancer growth and metastasis by triggering miR-4291/ACSL4-Mediated ferroptosis. Frontiers in Oncology, 2022. 12.

150. Xiaofei, J., et al., Oleanolic acid inhibits cervical cancer Hela cell proliferation through modulation of the ACSL4 ferroptosis signaling pathway. Biochemical and Biophysical Research Communications, 2021. 545: p. 81-88.